These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30150466)

  • 21. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia.
    Nguyen D; Smith D; Vaughan-Jackson A; Magri A; ; Barnes E; Simmonds P
    J Hepatol; 2020 Oct; 73(4):794-799. PubMed ID: 32470499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
    Summa V; Ludmerer SW; McCauley JA; Fandozzi C; Burlein C; Claudio G; Coleman PJ; Dimuzio JM; Ferrara M; Di Filippo M; Gates AT; Graham DJ; Harper S; Hazuda DJ; Huang Q; McHale C; Monteagudo E; Pucci V; Rowley M; Rudd MT; Soriano A; Stahlhut MW; Vacca JP; Olsen DB; Liverton NJ; Carroll SS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4161-7. PubMed ID: 22615282
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Han B; Parhy B; Lu J; Hsieh D; Camus G; Martin R; Svarovskaia ES; Mo H; Dvory-Sobol H
    J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30728196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
    Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.
    Camus G; Han B; Asselah T; Hsieh D; Dvory-Sobol H; Lu J; Svarovskaia E; Martin R; Parhy B; Miller MD; Brainard DM; Kersey K; Abergel A; Mo H
    J Viral Hepat; 2018 Feb; 25(2):134-143. PubMed ID: 28984067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
    Lawitz EJ; Dvory-Sobol H; Doehle BP; Worth AS; McNally J; Brainard DM; Link JO; Miller MD; Mo H
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5368-78. PubMed ID: 27353271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
    Lawitz E; Poordad F; Anderson LJ; Vesay M; Kelly MM; Liu H; Gao W; Fernsler D; Asante-Appiah E; Robertson MN; Hanna GJ; Barr E; Butterton J; Kowdley KV; Hassanein T; Sahota A; Gordon SC; Yeh WW
    J Viral Hepat; 2019 Jun; 26(6):675-684. PubMed ID: 30739366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
    Schnell G; Krishnan P; Tripathi R; Beyer J; Reisch T; Irvin M; Dekhtyar T; Lu L; Ng TI; Xie W; Pilot-Matias T; Collins C
    PLoS One; 2018; 13(10):e0205186. PubMed ID: 30286205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
    Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
    Guo Z; Black S; Hu Y; McMonagle P; Ingravallo P; Chase R; Curry S; Asante-Appiah E
    J Biol Chem; 2017 Apr; 292(15):6202-6212. PubMed ID: 28228479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
    Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.
    Lin HM; Wang JC; Hu HS; Wu PS; Yang CC; Wu CP; Pu SY; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yeh TK; Yueh A
    Antimicrob Agents Chemother; 2012 Jan; 56(1):44-53. PubMed ID: 22006008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors.
    Toyodome A; Mawatari S; Eguchi H; Takeda M; Kumagai K; Taniyama O; Ijuin S; Sakae H; Tabu K; Oda K; Ikeda M; Ido A
    Sci Rep; 2024 Jul; 14(1):16363. PubMed ID: 39013947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
    Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
    J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor.
    Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Wong KA; Jones CT; Jiang L; Lin K; Or YS
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6216-26. PubMed ID: 27503644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus NS5A inhibitors and drug resistance mutations.
    Nakamoto S; Kanda T; Wu S; Shirasawa H; Yokosuka O
    World J Gastroenterol; 2014 Mar; 20(11):2902-12. PubMed ID: 24659881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase.
    Lemm JA; Liu M; Gentles RG; Ding M; Voss S; Pelosi LA; Wang YK; Rigat KL; Mosure KW; Bender JA; Knipe JO; Colonno R; Meanwell NA; Kadow JF; Santone KS; Roberts SB; Gao M
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3485-95. PubMed ID: 24733465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.